Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status

View Full Paper
Ask AI
Bookmark
Share

Authors

JNJuliet NdukumNFNicole FulcherDADavid Andorsky

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows second line therapy outcomes in patients with R/R DLBCL, indicating the need for better treatment options.

Key Points

  • This research aims to evaluate the characteristics and outcomes of patients with relapsed/refractory DLBCL receiving second line therapy.
  • Retrospective analysis of adult patients treated with 2L therapies for R/R DLBCL
  • Data abstracted from electronic health records between 2016 and 2023
  • Outcomes assessed included real-world response rates, progression-free survival, and overall survival.
  • Majority of patients did not receive ASCT or CAR-T therapy
  • Only 16% of patients received CAR-T after second line treatment initiation
  • Median real-world progression-free survival for ASCT patients was 32.8 months, compared to 4.7 months for non-ASCT patients.

Cite This Study

Ndukum et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0bfhttps://doi.org/10.1182/blood-2025-8063
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy2024 · 18 citations
  2. 2A Real‐World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B‐Cell Lymphoma2026
  3. 3Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry2025
  4. 4Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States2025
  5. 5Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study2026